The global heart failure therapeutics market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Heart failure is a medical condition caused due to abnormal cardiac structure and function. Heart failure is a chronic progressive disorder that affects the blood pumping capacity of the heart muscles, leading to an insufficient supply of blood to the whole body. Heart failure has a significant burden on the global healthcare system, affecting more than 26 million people across the globe. It is estimated that heart failure across the globe had cost around $100 billion in 2012. Among these, the growing global population suffering from cardiovascular illnesses is the primary factor for the increased market growth. 

Globally, almost 15 million people suffer from heart attacks or similar issues, according to the World Heart Federation. Six million of these patients will die, while another five million will be severely crippled. In the US, one person dies from CVD every 36 seconds. Heart disease claims the lives of around 659,000 people in the US each year, accounting for one out of every four mortalities. Between 2016 and 2017, the US spent $363 billion on heart disease. This covers the costs of healthcare services, medications, and lost productivity as a result of mortality. The most frequent type of heart illness, coronary heart disease, killed 360,900 people in 2019. These diseases affect approximately 18.2 million persons aged 20 and up (about 6.7%). Adults under the age of 65 account for about 2 out of every 10 mortalities due to coronary artery disease. This results in the rising incidences of heart failure, which in turn, is driving the growth of the global heart failure therapeutics market. 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Heart Failure Stage
• By Drug Class
• By Distribution Channel

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  Amgen Inc., Johnson & Johnson Services, Inc., and Novartis International AG, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Heart Failure Therapeutics Market Report by Segment

By Heart Failure Stage

• Class I
• Class II
• Class III
• Class IV

By Drug Class

• Angiotensin-Converting Enzyme Inhibitors 
• Angiotensin Receptor Blockers 
• Diuretics
• Beta Blockers
• Procoralan
• Mineralocorticoid Receptor Antagonists
• Others

By Distribution Channel

• Hospital Pharmacy 
• Retail Pharmacy 
• Online Pharmacy 

Global Heart Failure Therapeutics Market Report by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa